Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211458 · ClinicalTrials.gov registry record · Phase 2
Treatment of Age-Related Macular Degeneration With Anecortave Acetate
A Phase 2 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00211458 is a Phase 2 study that has completed, run by Manhattan Eye, Ear & Throat Hospital.
The verdict
NCT00211458, a Phase 2 study, has completed, sponsored by Manhattan Eye, Ear & Throat Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control classic neovascularization following failure of treatment with photodynamic therapy using Visudyne.
Interventions
- DRUG Anecortave Acetate Sterile Suspension (15 mg)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-09 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00211458
The ClinicalTrials.gov registry entry for NCT00211458 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Manhattan Eye, Ear & Throat Hospital, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anecortave Acetate Sterile Suspension (15 mg) is the first listed.
NCT00211458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00211458 about?
NCT00211458 is a clinical study titled "Treatment of Age-Related Macular Degeneration With Anecortave Acetate". The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control classic neovascularization following failure of treatment with photodynamic therapy using Visudyne.
What is the current status of trial NCT00211458?
This trial is currently completed. It is a Phase 2 study. The study started on 2005-09. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00211458?
The interventions under investigation include: Anecortave Acetate Sterile Suspension (15 mg) (DRUG).
Who is sponsoring clinical trial NCT00211458?
This trial is sponsored by Manhattan Eye, Ear & Throat Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.